Introduction:

Transarterial radioembolization (TARE) is an alternative therapy for the treatment of unresectable liver tumors.

Method:

Retrospective and descriptive study in 27 patients undergoing TARE with Ytrio-90-loaded resin microspheres. Baseline, demographic and clinical characteristics were studied, and overall survival at 18 months was analyzed using the Kaplan-Meier method.

Results:

Age ranged between 52-85 years, and 81% of patients were men. 78% presented primary liver tumors, highlighting hepatocellular carcinoma BCLC (Barcelona Clinic Liver Cancer) stage B (HCC BCLC B) (44%). The origin of the most frequent secondary liver tumor was colorectal adenocarcinoma. The ECOG (Eastern Cooperative Oncology Group) was 0 for 78% of the patients and the antecedents were alcoholism (41%) and hepatitis C (56%). The average administered activity was 1.8 GBq. 34% received more than one previous treatment: surgical resection (11%), transarterial embolization or chemoembolization (48%), radiofrequency ablation (22%) or multi-kinase inhibitors (15%). 33% received subsequent treatment with multi-kinase inhibitors. The overall survival at 18 months was 58.9%. In patients with HCC BCLC B, the median survival was 15.6 months.

Conclusion:

The survival results are in line with those of other studies, although there are differences in some of the variables. It is necessary to have more patients and follow-up time to analyze its influence on survival.

        · resumen en Español     · texto en Español     · Español ( pdf )